ADZYNMA 1.500 UI POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE

USDailyMed:Apadamtase alfa None US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 2086325-24-6 DB15164 U5SFU33XUX D12569 Apadamtase alfa, sold under the brand nameAdzynma, is anenzyme replacement therapyused for the treatment ofthrombotic thrombocytopenic purpura.Apadamtase alfa is a human recombinanta disintegrin and metalloproteinase with thrombospondin motifs 13.It is given by injection into a vein. The most common side effects include headache, diarrhea, migraine, abdominal pain, nausea, upper respiratory tract infection, dizziness and vomiting. During the clinical studies, no adverse events, including allergic reactions, were observed during the administration of Adzynma. Apadamtase alfa was approved for medical use in the United States in November 2023,and in the European Union in August 2024.